NeuroHagana Ltd.
NeuroHagana is a biotechnology company focused on developing an acute, injectable neuroprotective therapy intended to be administered within hours after brain or spinal cord injury. The approach aims to reduce secondary neuronal damage by lowering blood glutamate levels to facilitate efflux of excess glutamate from the central nervous system. The program is supported by preclinical efficacy data in multiple animal models and a team with experience in translational pharmacology, CMC and preclinical neuroscience.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Acute injectable neuroprotective therapeutic (preclinical candidate)
First-in-class injectable candidate intended for early post-injury administration to lower blood glutamate and reduce secondary neuronal tissue damage after neurotrauma.
Acute injectable neuroprotective therapeutic (preclinical candidate)
First-in-class injectable candidate intended for early post-injury administration to lower blood glutamate and reduce secondary neuronal tissue damage after neurotrauma.
Expertise Areas
- Acute neurotrauma therapeutics
- Preclinical in vivo models for TBI, SCI and concussion
- Translational and clinical pharmacology
- CMC and injectable formulation development
Key Technologies
- Blood glutamate reduction to mitigate excitotoxicity
- Injectable neuroprotective formulation development
- In vivo preclinical models of neurotrauma (TBI, SCI, concussion)
- Preclinical pharmacology and mechanism-of-action studies
News & Updates
Company CEO presented the neuroprotective platform at the 2nd Annual SCI Investor Symposium (San Diego).
Featured in Praxis Spinal Cord Institute focus group brochure (spinal cord injury focus).
Featured in a Wings for Life compilation of promising spinal cord injury research projects.
News article reporting on research that may reduce nerve-cell damage and improve mobility after spinal injury.
Company CEO presented the neuroprotective platform at the 2nd Annual SCI Investor Symposium (San Diego).
Featured in Praxis Spinal Cord Institute focus group brochure (spinal cord injury focus).
Featured in a Wings for Life compilation of promising spinal cord injury research projects.
News article reporting on research that may reduce nerve-cell damage and improve mobility after spinal injury.